Canada markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5200+0.0200 (+1.33%)
At close: 04:00PM EDT
1.4900 -0.03 (-1.97%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.5000
Open1.5200
Bid1.5000 x 300
Ask1.5300 x 100
Day's Range1.4900 - 1.5300
52 Week Range0.6200 - 2.3100
Volume499,220
Avg. Volume1,024,125
Market Cap191.151M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

    FDA Update to Mammography Regulations in MQSA Final Rule is Effective TodaySEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for issuing a final rule to update the mammography regulations issued under the Mammography Quality Standards Act of 1992 (MQSA), which becomes effective today. Among the updates, the final rule requires mammography facilities to provid

  • GlobeNewswire

    Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

    SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat and meet with investors. A recording of the fireside chat will be available here at 7:00

  • GlobeNewswire

    Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

    SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a cli